Question: What year was the pharmaceutical company that markets Mylotarg purchased by Pfizer?

Context articles: Gemtuzumab ozogamicin
King Pharmaceuticals
Wyeth
Lupin Limited
Charles Pfizer
Franklin v. Parke-Davis
Pfizer UK
Peter Rost (doctor)
Abdullahi v. Pfizer, Inc.
Ethchlorvynol

Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010.
 It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.
 It was re-introduced into the US market in 2017.
King Pharmaceuticals, is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee.
 Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company.
 On October 12, 2010, King was acquired by Pfizer for $14.25 per share.
 King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant.
 King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin.
 They employed approximately 2,700 people including a sales force of over 1,000 individuals.
Wyeth was a pharmaceutical company purchased by Pfizer in 2009.
 The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother.
 It was later known as American Home Products before being renamed to Wyeth in 2002.
 Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.
 The infant and maternal nutrition business was acquired by Nestlé in 2012.
Lupin Limited is a transnational pharmaceutical company based in Mumbai.
 It is the seventh-largest company by market capitalization; and the 10th-largest generic pharmaceutical company by revenue globally.
 Lupin is the fifth-largest generic pharmaceutical company in the US by prescription-led market share and 3rd largest Indian pharmaceutical company by revenue.
 It has the distinction of being the fastest growing generic pharmaceutical player in the US and Japan;, and is the 4th largest and the fastest growing generic pharmaceutical player in South Africa.
Karl Gustav Pfizer (March 22, 1824 – October 19, 1906), known as Charles Pfizer, was a German-American chemist who founded, with his cousin and future brother-in-law Charles F. Erhart, the Pfizer Inc. pharmaceutical company in 1849 as Charles Pfizer & Co.
Franklin v. Parke-Davis is a lawsuit filed in 1996 against Parke-Davis, a division of Warner-Lambert Company, and eventually against Pfizer (which bought Warner-Lambert in 2000) under the "qui tam" provisions of the False Claims Act.
 The suit was commenced by Dr. David Franklin, a microbiologist hired in the spring of 1996 in a sales capacity at Parke-Davis, a pharmaceutical subsidiary of Warner-Lambert (Warner-Lambert was subsequently acquired by Pfizer in 2000).
 In denying the defendants' motion for summary judgment, the court for the first time recognized off-label promotion of drugs could cause Medicaid to pay for prescriptions that were not reimbursable, triggering False Claims Act liability.
 The case was also significant in exposing the degree to which publication bias impacts the randomized controlled studies conducted by pharmaceutical companies to test the efficacy of their products.
 Ultimately, the parties reached a settlement agreement of $430 million to resolve all civil claims and criminal charges stemming from the "qui tam" complaint.
 At the time of the settlement in May 2004, it represented one of the largest False Claims Act recoveries against a pharmaceutical company in U.S. history, and was the first off-label promotion settlement under the False Claims Act.
Pfizer UK (officially Pfizer Ltd) is the principal subsidiary of the multinational pharmaceutical company Pfizer in the United Kingdom.
Peter Rost, M.D. is a former drug marketing executive and is most known for taking public stances critical of the pharmaceutical industry as an "insider" and whistleblower.
 He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005.
 At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey.
 Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion.
 Rost settled with Wyeth for an undisclosed amount in 2003.
 At Pfizer, Rost filed a "qui tam" suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer.
 The U.S. Department of Justice declined to join in Rost's suit as the marketing violations had already been disclosed to the Department by Pfizer.
 Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities.
 Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant.
The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the pharmaceutical company Pfizer in 1996 in Kano, Nigeria, during an epidemic of meningococcal meningitis.
 To test its new antibiotic, trovafloxacin (Trovan), Pfizer gave 100 children trovafloxacin, while another 100 received the gold-standard anti-meningitis treatment, ceftriaxone, a cephalosporin antibiotic.
 Pfizer gave the children a substantially reduced dose of the ceftriaxone (specifically, 33mg/kg) relative to that described on the US FDA approved Prescribing Information.
 The allegation is that this was done to skew the test in favor of its own drug.
 Pfizer claimed that the dose used was sufficient even though a clinical trial performed by Médecins Sans Frontières recommends a dose of 50 - 100mg/kg.
 A 2002 report by the World Bank described the military government that ruled Nigeria at the time of these events as "pervasively corrupt".
 It further cites widespread comments by business managers in Nigeria characterizing the NAFDAC of that period as lacking the capabilities needed to perform its regulatory role and "harassing business and seeking bribes" rather than "protecting businesses and consumers".
Ethchlorvynol is a GABA-ergic sedative and hypnotic/soporific medication developed by Pfizer in the 1950s.
 In the United States it was sold by Abbott Laboratories under the tradename Placidyl.
 Placidyl was available in 200 mg., 500 mg., and 750 mg.
 strength capsules.
 While the 500 mg.
 and 750 mg.
 strength capsules were for use in reducing sleep latency, the 200 mg.
 strength capsules were intended to be used to re-induce sleep in case of early awakening.
 Abbott discontinued production in 1999, after which Placidyl was available for about a year in the United States.
 Although, theoretically, ethchlorvynol could be manufactured for sale in the United States by another pharmaceutical company (subject to FDA approval of such manufacture), no pharmaceutical company has chosen to do so.
 Individuals with a valid prescription for the substance may legally transport a reasonable amount of ethclorvynol with them into the United States.